The challenge with controlling the differentiation of human pluripotent cells to generate functional dopaminergic neurons for the treatment of Parkinson's disease has undergone significant progress in recent years. Here, we summarize the differences between newer and older protocols for generating midbrain dopaminergic neurons from human pluripotent stem cells, and we highlight the importance of following developmental pathways during differentiation. The field has now developed to a point where it is timely to take human pluripotent stem cells one step closer to clinical use, and cell criteria to be fulfilled for such developments are outlined in this review.
of-principle that neuronal replacement can also be effective in the disease-affected human brain. The grafted neurons were able to survive, reinnervate the striatum, and normalize striatal dopamine (DA) release leading to substantial clinical benefits, and in some patients even allowed for withdrawal of L-DOPA treatment 
Previous and current strategies of hESC neuralization and patterning
Since
Building mesda progenitors through developmental pathways
The lack of success in generating functional DA neurons of a mesencepahlic identity was explained when it was revealed that mesDA neurons have their cellular origin from the midbrain floor plate rather than from the neuroepithelium and that the floor plate transcription factor FOXA2 is an important gene necessary for correct mesDA specification and maintenance [16] [17] [18] [19] . In rodents and humans, The enzyme tyrosine hydroxylase (TH) is a required enzyme for DA synthesis, and is often used as a key marker of DA neurons. Although absence of TH expression clearly excludes DA identity, its presence alone is not sufficient to determine a DA neuron phenotype. For example, noradrenergic (NA) neurons rely on TH expression [35] , and the enzyme has also been found in subpopulations of GABAergic neurons of the striatum, olfactory bulb and cortex [36] [37] [38] [39] .
In addition to this, several studies have revealed that TH expression can be influenced by various external factors applied to neurons in vitro. Striatal cultures, which are normally devoid of DA neurons, can be induced to express TH in a high proportion of neurons when exposed to factors such as aFGF, FGF1, FGF2, BDNF, DA, activin and serum [40] [41] [42] [43] . Importantly, the TH induction in these neurons is transient and it often occurs in cells, which also express markers of GABAergic neurons (i.e. GABA and Gad67).
The plasticity of TH expression in forebrain cultures in vitro may reflect the fact that some forebrain neurons transiently express TH during development [39, 44, 45] . It is possible that this transient neuronal state may be reinforced or captured by certain external factors, giving rise to apparent dopaminergic neurons in cell cultures.
Therefore, when aiming to produce neurons for cell replacement in PD, DA identity of TH expressing cells produced in vitro should always be confirmed using additional markers of mesencephalic cells and dopamine neurons coupled with the absence of GABA. is an activator of hindbrain genes and not of midbrain genes [26, 27] . rostro-caudal patterning is mediated through a WNT gradient secreted from the paraxial mesoderm, and dorso-ventral patterning is mediated through secretion of BMP from the roof plate and SHH from the floor plate. FB: forebrain, MB: midbrain, HB: hindbrain, SC: spinal cord. B. Chemical inhibition of GSK3 with the compound CT99021/CHIR99021 can dose-dependently activate WNT signalling in hESC, and thereby induce gradual rostro-caudal patterning of neural fates from forebrain to hindbrain; equivalent to the situation in the developling neural tube. The dorso-ventral identity of the neural fates can be further controlled by SHH and BMP signalling in vitro (summary of data shown in [24] ). In vivo characteristics, grafts:
Conclusion
• Absence of pluripotency markers
• High proportion of neurons expressing TH, DAT and VMAT but not GABA/Gad67
• Expression of GIRK2 and PITX3
• Mature morphology and extensive innervation
• DA release and restoration of motor function References
